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Background
After successful treatment of malignant diseases, therapy-related myelodysplastic syn-
drome and acute myeloid leukemia have emerged as significant problems. 
Design and Methods
The aim of this study was to investigate outcome and risk factors in patients with thera-
py-related myelodysplastic syndrome or acute myeloid leukemia who underwent allo-
geneic stem cell transplantation. Between 1981 and 2006, 461 patients with therapy-relat-
ed myelodysplastic syndrome or acute myeloid, a median age of 40 years and a history of
solid tumor (n=163), malignant lymphoma (n=133), or other hematologic diseases (n=57)
underwent stem cell transplantation and their data were reported to the European Group
for Blood and Marrow Transplantation.
Results
The cumulative incidence of non-relapse mortality and relapse at 3 years was 37% and
31%, respectively. In a multivariate analysis significant factors for relapse were not being
in complete remission at the time of transplantation (p=0.002), abnormal cytogenetics
(p=0.005), higher patients’ age (p=0.03) and therapy-related myelodysplastic syndrome
(p=0.04), while higher non-relapse mortality was influenced by higher patients’ age.
Furthermore, there was a marked reduction in non-relapse mortality per calendar year dur-
ing the study period (p<0.001). The 3-year relapse-free and overall survival rates were 33%
and 35%, respectively. In a multivariate analysis significant higher overall survival rates
were seen per calendar year (p<0.001), for younger age (<40 years) and normal cytogenet-
ics (p=0.05). Using age (<40 years), abnormal cytogenetics and not being in complete
remission at the time of transplantation as risk factors, three different risk groups with
overall survival rates of 62%, 33% and 24% could be easily distinguished.
Conclusions
Allogeneic stem cell transplantation can cure patients with therapy-related myelodysplas-
tic syndrome and acute myeloid leukemia and has markedly improved over time. Non-
complete remission, abnormal cytogenetics and higher patients’ age are the most signifi-
cant factors predicting survival. 
Key words: allogeneic stem cell transplantation, therapy-related, myelodysplastic
syndrome, acute myelogenous leukemia, cytogenetic abnormalities.
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ABSTRACT
Introduction
Chemotherapy and/or radiotherapy as part of a multi-
modal treatment approach in cancer patients has led to an
increase in the cure rate. After successful treatment of
cancer, late effects such as therapy-related myelodysplas-
tic syndrome (MDS) and acute myeloid leukemia (AML)
have emerged as significant problems.1 With the increas-
ing cure rate for some malignancies due to intensified
chemotherapies including total body irradiation and
autologous stem cell support, there seems to be an
increasing incidence of therapy-related MDS (t-MDS) and
therapy-related AML (t-AML).2 Primary MDS, AML after
MDS and t-MDS/t-AML share biological and clinical fea-
tures, but t-MDS/t-AML are more rapidly progressive dis-
eases and respond less well chemotherapy.3-6 
Two different types of treatment-related leukaemia can
be distinguished. The first type results from prior therapy
with alkylating agents or radiation therapy and occurs
after a latency period of 5 to 7 years. This type of AML is
often preceded by a preleukemic period of myelodyspla-
sia. Up to 90% of the patients with alkylating-agent-relat-
ed MDS or AML show clonal chromosomal aberrations
including monosomy or deletions on chromosomes 5
and/or 7 or complex aberrations involving chromosomes
3, 12, 17, and 21.7 The second type of therapy-related
leukemia is induced by topo-isomerase II-targeted drugs,
such as etoposide, anthracyclines, and anthracenedione.8-
10 This type of AML usually occurs after a median of 2
years, and is not preceded by a MDS. According to the
French-American-British (FAB) classification, M4 and M5
subtypes are observed more frequently, and cytogenetic
analysis shows a high frequency of rearrangements of
chromosome band 11q23, t(8;21), t(15;17), inv(16) or
t(8;16) as in de novo-AML.10,11 Importantly the small num-
ber of patients with t-AML who have favorable cytoge-
netic abnormalities, such as t(8;21), t(15;17) or inv(16),
have a considerably better outcome, not markedly differ-
ent from that observed in patients with de novo AML with
the same abnormalities.12
In a recent analysis of autologous stem cell transplanta-
tion in 65 patients with t-AML/t-MDS of the MDS-
Subcommittee of the Chronic Leukaemia Working Party
of the European Group for Blood and Marrow
Transplantation (EBMT), 3-year overall and event-free
rates of 35% and 32%, respectively, were reported.
Younger age and transplantation in first complete remis-
sion were significant factors for improved survival.13 In a
French series of allogeneic stem cell transplantation in
patients with secondary MDS/AML, 2-year event-free
and overall survival rates of 28% and 30%, respectively,
were reported.14 More recently, Chang reported on 257
patients with secondary MDS or t-AML who underwent
allogeneic stem cell transplantation. They found that
relapse-free survival correlated significantly with disease
stage and karyotype.15 The authors compared the results
in patients with secondary MDS/t-AML with those in
patients with de novo-MDS/secondary AML and found no
differences in outcome after adjustment for diseases sta-
tus and cytogenetics, suggesting that outcome is deter-
mined mainly by disease characteristics rather than by
etiology. Other studies indicated that cytogenetic abnor-
malities represent a major prognostic factor for outcome
of patients with t-MDS;16 after adjustment for cytogenet-
ic risk factors, no major difference between de novo- and t-
MDS could be observed following allogeneic stem cell
transplantation.17
In order to shed light on these issues, we conducted an
analysis of the outcome and risk factors in patients with
t-MDS/t-AML who underwent allogeneic stem cell
transplatation.
Design and Methods
Between 1981 and 2006, 461 patients with t-MDS or t-
AML underwent first allogeneic stem cell transplantation,
and their data were reported to the EBMT registry. The
median age of the patients was 40 years (range, 3-69), and
their primary disease was a solid tumor (n=163), malig-
nant lymphoma (n=133), or other hematologic disease
(n=57). For those patients with information about treat-
ment of primary disease (n=108) this treatment consisted
of chemotherapy (50%), chemotherapy plus radiotherapy
(32%), only radiotherapy (10%) or high-dose chemother-
apy followed by autologous stem cell support (7%). The
time from primary diagnosis to t-MDS/t-AML was 54
months (range, 1-417 months) and from t-MDS/t-AML to
allogeneic stem cell transplantation 6 months (range, 1-
278 months). The number of older patients increased over
time: between 1981 and 1989 only 3% of the patients
were older than 50 years of age, between 1990 and 1999
this population increased to 18% and between 2000 and
2006 39% of the patients were older than 50 years of age.
t-AML without preceding MDS was noted in 293
patients, whereas 168 patients had MDS at diagnosis.
Cytogenetic data were available for 340 patients, who
could be divided into having normal cytogenetics (n=83)
or abnormal cytogenetics (n=253).
The median follow-up of the surviving patients is 21
months (range, 1-177). The patients’ characteristics are
shown in Table 1.
Statistical analyses
For the Kaplan-Meier curves (used in univariate descrip-
tions) and Cox models (used to estimate hazard ratios,
[HS]) the relapsed patients were censored for transplant-
related mortality at the time of relapse and vice versa.
Univariate comparison of Kaplan-Meier curves was per-
formed using the two-tailed log-rank test. For ordered cat-
egorical variables, the trend version of the log-rank test
was used. The association of various risk factors such as
age, remission status at transplantation, stem cell source,
time from primary diagnosis to diagnosis of t-MDS/t-
AML, type of treatment-related disease, presence of cyto-
genetic abnormalities, and total body irradiation-contain-
ing conditioning with the outcomes (overall survival,
relapse-free survival, relapse incidence and transplant-
related mortality) was quantified using the hazard ratios
estimated in the Cox models.
Relapse incidence and therapy-related mortality were
calculated using cumulative incidence estimates.
Calculations were performed with SPSS version 12.0. The
Allogeneic stem cell transplantation for t-MDS/AML
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cumulative incidences were calculated with SPSS 14.0
using a macro developed at the Department of Medical
Statistics (LUMC).
Results
Non-relapse mortality
The non-relapse mortality rate at 1 year was 32%, and at
3 years 37%. Significant factors for higher non-relapse
mortality were transplantation before 1998 (p=0.001),
occurrence of acute graft-versus-host disease (p=0.02),
patient’s age (>40 years; p=0.002), not being in complete
remission at the time of transplantation (p=0.01), interval
of more than 54 months from diagnosis of primary disease
to diagnosis of t-MDS/t-AML (p=0.001) and t-MDS at
diagnosis (in comparison to t-AML at diagnosis) (p=0.02)
(Table 2).
In a multivariate analysis, a continuous improvement per
year in non-relapse mortality was noted [HR: 0.92; 95%
confidence interval (CI): 0.89-0.96, p<0.001] (Figure 1). The
age of the patient also significantly influenced non-relapse
mortality: 40-50 years (HR: 2.6; 95% CI: 1.47-4.47,
p=0.001) vs. over 50 years (HR: 2.0; 95% CI: 1.06-3.62,
p=0.03). An unknown time-interval from diagnosis of pri-
mary disease to diagnosis of t-MDS/t-AML was significant
in the multivariate analysis (HR: 1.8; 95% CI: 1.08-3.05,
p=0.02) (Table 3).
Relapse
The cumulative incidence of relapse at 3 years was 31%.
Significant factors for a higher relapse rate at 3 years were
intermediate and high-risk cytogenetics (p=0.04), non-
occurrence of acute graft-versus-host disease (p=0.05), not
being in complete remission at the time of transplantation
(p=0.05), a conditioning regimen not cintaining total body
irradiation (p=0.04), an interval of less than 54 months
between primary diagnosis and diagnosis of t-MDS/t-AML
(p=0.02), and patient’s age greater than 40 years (p=0.02)
(Table 3).
In a multivariate analysis, abnormal cytogenetics (HR:
2.1; 95% CI: 1.24-3.55, p=0.005), not being in complete
remission at the time of transplantation (HR: 2.3; 95% CI:
1.37-3.83, p=0.002), age 40-50 years (HR: 1.9; 95% CI:
continued from previous column.
Conditioning 
Standard intensity n=335
Reduced intensity n=112
Missing n=14
Interval from diagnosis of t-MDS/t-AML to allogeneic SCT
< 6 months n=236
6-12 months n= 145
> 12 months n=80
Interval from diagnosis of primary disease to diagnosis
of t-MDS/t-AML
0-54 months n=184
> 54 months n=183
Missing n=94
RA: refractory anemia; RARS: RA with ringed sideroblasts; RAEB: RA with excess
blasts; RAEB-t: RAEB in transformation; SCT: stem cell transplantation.
Table 1. Patients’ characteristics.
Number of patients n=461
Age (median) 40 years (range,  
3-69 years)
≤40 years n=236
> 40 years n=225
Gender 
Male n=193
Female n=268
Cytomegalovirus-status of recipients
Negative n=230
Positive n=231
HLA-status of donor
Identical sibling n=290
Matched other relative n=7
Matched unrelated n=95
Mismatched relative n=28
Mismatched unrelated n=41
Origin of t-MDS / t-AML 
Lymphoma n=133
Solid tumor n=163
Other hematologic disease n=57
Missing n=108
Cytogenetics 
Normal n=87
Abnormal n=253
Unknown / missing n=121
Cytogenetic risk 
Low (normal and t(8;21),inv 16 or t(15;17) n=103
Intermediate (one ot two abnormalities not low or high) n=47
High (11q; t(6;9); -7; del(7q); del 5q or complex (≥3) n=111
Missing n=200
Conditioning
Total body irradiation n=209
Not total body irradiation n=239
Missing n=13
Diagnosis at transplantation
RA / RARS n=28
RAEB n=49
RAEB-t n=44
t-AML n=308
Unknown n=32
At diagnosis and transplantation 
AML at diagnosis and transplantation n=293
MDS at diagnosis and MDS or AML at transplantation n=168
Acute graft-versus-host disease 
None n = 185
Grade I n = 107
Grade II n = 73
Grade III n = 39
Grade IV n = 26
Missing n = 26
Stem cell source 
Bone marrow n=274
Peripheral blood stem cells n=187
Transplantation 
Before 1998 n = 183
After 1998 n = 278
Stage at transplantation 
Complete remission n=264
Not in complete remission n=175
Missing n=22
To be continued on next column.
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Table 2. Univariate analysis of relapse-free and overall survival.
Non-relapse mortality Relapse incidence Relapse-free survival Overall survival
All probabilities Cumulative p value Cumulative p value Probability p value Probability p value
estimated at 3 years incidence [log-rank] incidence [log-rank] % %
% %
All patients 37 31 33 35
Disease status
RA/RARS 23 37 41 48
RAEB 47 0.6 28 0.7 25 0.8 28 0.6
RAEB-t 51 33 15 20
secondary AML 33 32 36 38
Donors' gender 
male 37 0.8 32 0.8 31 0.7 34 0.8
female 37 30 33 35
Donor 
related 36 0.8 32 0.1 32 0.3 33 0.3
unrelated 38 28 34 40
Recipients' CMV status 
positive 38 0.2 31 0.3 30 0.08 31 0.07
negative 35 30 35 39
Stem cell source 
bone marrow 41 0.06 27 0.2 32 0.6 35 0.6
peripheral blood 31 35 33 33
Interval from diagnosis of t-MDS/t-AML to SCT
<6 months 34 0.6 32 0.3 34 0.8 35 0.7
6–12 months 40 30 30 32
>12 months 40 27 33 39
Primary disease 
non Hodgkin’s lymphoma 42 0.2 32 0.6 26 0.2 30 0.3
solid tumors 30 33 37 39
Conditioning
reduced-intensity 29 0.5 44 0.2 26 0.8 34 0.9
standard-intensity 39 28 34 35
unknown 43 20 38 38
Conditioning
TBI 38 26 36 37
non-TBI 36 0.9 35 0.04 29 0.2 33 0.5
unknown 38 27 35 35
T-cell depletion 
yes 36 0.9 33 0.7 31 0.8 35 0.9
no 35 31 35 37
Stem cell transplantation 
before 1998 45 0.001 28 0.8 27 0.009 29 0.02
after 1998 30 33 37 40
Cytogenetics 
normal 33 21 46 47
abnormal 33 0.02 37 0.2 30 0.01 34 0.01
unknown 46 27 27 30
Cytogenetic risk profile 
low 33 19 48 49
intermediate 34 0.1 37 0.04 30 0.01 31 0.02
high 36 39 26 29
unknown 40 31 29 32
Acute GvHD 
no 26 38 36 39
yes 43 0.02 27 0.05 30 0.6 32 0.3
unknown 44 22 34 34
Patients' age
≤ 40 years 32 0.002 28 0.02 40 < 0.001 42 < 0.001
> 40 years 43 34 24 26
Remission status prior to SCT
CR 32 0.01 28 0.05 40 0.001 42 0.004
non-CR 43 35 21 25
unknown 36 19 45 44
Interval from primary disease to diagnosis of t-MDS/AML 
0-54 months 27 0.001 36 0.02 37 0.3 40 0.2
> 54 months 40 33 27 30
Unknown 48 18 34 36
At diagnosis and transplantation 
AML at diagnosis 32 0.02 32 0.9 36 0.1 38 0.06
and transplantation
MDS at diagnosis and MDS 44 29 27 30
or AML at transplantation
RA: refractory anemia; RARS: RA with ringed sideroblasts; RAEB: RA with excess blasts; RAEB-t: RAEB in transformation; CMV: cytomegalovirus; SCT: stem cell transplantation; TBI:
total body irradiation; GvHD: graft-versus-host disease; CR: complete remission.
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1.07-3.51, p=0.03) and t-MDS (HR: 0.6; 95% CI: 0.36-0.99,
p=0.04) were the independent significant factors for pre-
dicting the incidence of relapse (Table 3).
Relapse-free survival
The estimated 3-year relapse-free survival was 33%. In
the univariate analysis, significant factors for an improved
3-year relapse-free survival rate were stem cell transplanta-
tion after 1998 (p=0.009), normal or low-risk cytogenetics
(p=0.01), patient’s age under 40 years (p<0.001), and stem
cell transplantation in complete remission (p=0.001). (Table
3). In a multivariate analysis, year of transplantation, as a
continuous variable, was highly significant for improved
relapse-free survival (HR: 0.95; 95% CI: 0.93-0.98,
p=0.002). Further independent factors for an improved
relapse-free survival in multivariate analysis were abnor-
mal cytogenetics (HR: 1.4; 95% CI: 1.04-1.99, p=0.03), not
being in complete remission at the time of transplantation
(HR: 1.6; 95% CI: 1.16-2.33, p=0.006), patients’ age of 40-
50 years (HR: 2.3; 95% CI: 1.51-3.40, p<0.001) and over 50
years old (HR: 1.9; 95% CI: 1.22-2.91, p=0.004) (Table 3).
Overall survival
The estimated overall survival at 3 years was 35%.
Significant factors for improved overall survival at 3 years
were stem cell transplantation after 1998 (p=0.02), patient’s
age less than 40 years (p<0.001), being in complete remis-
sion at the time of transplantation (p=0.004) and low-risk
cytogenetics (p=0.02). A trend for improved survival at 3
years was seen in patients with t-AML without preceding
MDS (p=0.06), and in patients who were cytomegalovirus-
Table 3. Multivariate analysis of overall survival, relapse-free survival, relapse and non-relapse mortality [HR: (95% CI:).
Overall survival p value Relapse-free p value Relapse p value Non-relapse p value
HR (95% CI) survival mortality
Year of transplantation 0.95 (0.92-0.98) <0.001 0.95 (0.93-0.98) 0.002 1.0(0.95-1.04) 0.74 0.92 (0.89-0.96) < 0.001
Patients' age
<30 years 1.0 1.0 1.0 1.0
30-40 years 1.2 (0.73-1.84) 0.5 1.1 (0.70-1.74) 0.7 1.2 (0.59-2.25) 0.67 1.1 (0.60-2.08) 0.73
40-50 years 2.1 (1.42-3.24) < 0.001 2.3 (1.51-3.40) < 0.001 1.9 (1.07-3.51) 0.03 2.6 (1.47-4.47) 0.001
>50 years 2.0 (1.28-3.13) 0.002 1.9 (1.22-2.91) 0.004 1.7 (0.90-3.06) 0.11 2.0 (1.06-3.62) 0.03
Remission status prior to SCT
CR 1.0 0.08 1.0 0.006 1.0 1.0
non-CR 1.4 (0.96-1.94) 0.76 1.6 (1.16-2.33) 0.82 2.3 (1.37-3.83) 0.002 1.3 (0.77-2.02) 0.36
missing 1.1 (0.48-2.71) 1.1 (0.47-2.60) 0.5 (0.06-3.58) 0.47 1.5 (0.58-3.94) 0.39
Interval primary disease to t-MDS/t-AML 
0-54 months 1.0 1.0 1.0 1.0
≥ 54 month 1.2 (0.88-1.67) 0.23 1.2 (0.87-1.63) 0.27 1.3 (0.82-1.94) 0.29 1.1 (0.72-1.78) 0.6
Missing 1.2 (0.81-1.91) 0.32 1.2 (0.82-1.91) 0.30 0.6 (0.25-1.30) 0.18 1.8 (1.08-3.05) 0.02
Cytogenetics
normal 1.0 1.0 1.0 - -
abnormal 1.4 (0.99-1.94) 0.05 1.4 (1.04-1.99) 0.03 2.1 (1.24-3.55) 0.005
Group
t-AML 1.0 1.0 1.0 1.0 0.58
t-MDS 0.95 (0.67-1.34) 0.75 0.8 (0.60-1.19) 0.33 0.6 (0.36-0.97) 0.04 1.1 (0.71-1.84)
SCT: stem cell transplantation; CR: complete remission.
Figure 1. Overall survival, relapse-free survival, non-relapse mor-
tality and relapse incidence for patients with t-MDS/t-AML by cat-
egory of transplant year: before 1998 (<1998; n=183), 1998
onwards (≥1998; n=278).
Figure 2. Relapse incidence (A) and overall survival (B) in 261
patients with known cytogenetics classified as low (n=103), inter-
mediate (n=47), and high risk (n=111), (for risk categories see
text) (competing risk model). 
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negative (p=0.07) (Table 3). In multivariate analysis, a
marked improvement in survival was observed over time
(per calendar year) (HR: 0.95; 95% CI: 0.92-0.98, p<0.001).
Independent factors for impaired survival in the multivari-
ate analysis were age 40-50 years (HR: 2.1; 95% CI: 1.42-
3.24, p<0.001), and greater than 50 years (HR: 2.0; 95% CI:
1.28-3.13, p=0.002) and abnormal cytogenetics (HR: 1.4;
95% CI: 0.99-1.94, p=0.05), (Table 3).
Cytogenetic subanalysis
In 261 out of 340 patients with available cytogenetic
data a detailed cytogenetic sub-analysis could be per-
formed. This subgroup of patients was divided into a low-
risk group (n= 103) who had either (t(8;21), inv t(16),
t(15;17), (n=16) or a normal karyotype (n=87),  an interme-
diate risk group (n=47) (who had one or two abnormali-
ties), and a high-risk group (n=111) who had 11q23, t(6;9),
-7, del (7q), del (5q), or complex (≥3) abnormalities.
In this analysis, the cumulative incidence of relapse at 3
years was 19% for low-risk patients, 37% for intermedi-
ate risk patients, and 39% for high-risk patients (p=0.04),
while the non-relapse mortality did not differ at 3 years
(33%, 34%, 36% respectively; p=0.1) resulting in an
improved relapse-free and overall survival at 3 years for
the low-risk group in comparison to the intermediate and
high-risk patients [48% vs. 30% vs. 26% (p=0.01) and 49%
vs. 31% vs. 29% (p=0.02)]. (Figure 3).
Risk score
To develop a simple risk score for patients with t-
MDS/t-AML, we used the significant factors age, stage,
and cytogenetics. This risk score was based on a series of
Cox proportional hazards models. First, for each of four
possible outcomes (overall survival, relapse-free survival,
non-relapse mortality and relapse), using a stepwise back-
wards approach, a model was fitted eliminating non-sig-
nificant factors among age, stage,  cytogenetics, interval treat-
ment-diagnosis, total body irradiation and disease. After com-
paring the four resulting models, four new models were
fitted each containing those factors that were significant in
at least one of the stepwise-models. This ensures that the
same factors are used for all outcomes. For each outcome
the coefficients were compared among the predictors in
one model. The goal was to obtain a simple-to-use system
of penalty-points by rounding the coefficients to integers
without a specific statistical underlying criterion for opti-
mality. The three factors age, stage and cytogenetics were
found to have the highest weights and were taken into
account in the four reduced models, using integer coeffi-
cients only. The relative weights (effects) of age and stage
were different depending on the outcome modeled, as
described below; hence a compromise is needed if one wish-
es to use just one set of penalty points for all four out-
comes. For overall survival and non-relapse mortality,
points were given as follows: age over 40 years: +2; not in
complete remission: +1; and abnormal cytogenetics: +1.
For relapse were given: age over 40 years: +2; not in com-
plete remission: +2; and abnormal cytogenetics: +2. For
relapse-free survival the points asigned were: age over 40
years: +2; not in complete remission: +2; and abnormal
cytogenetics: +1. Patients were classified into groups at
low-risk, moderate-risk and high-risk as follows: overall sur-
vival and non-relapse-mortality (low: 0, 1; moderate: 2;
high: 3, 4); relapse (low: 0, 2; moderate: 4; high: 6); relapse-
free survival (low: 0, 1; moderate: 2, 3, high: 4, 5). This risk
model enables a clear classification into the following risk
groups: overall survival at 2 years: low: n=109 (60%);
moderate: n=78 (39%) and high: n=150 (25%)(p<0.001);
relapse-free survival at 2 years: low: n=146 (58%); moder-
ate: n=220 (32%) and high: n=95 (20%) (p<0.001); non-
relapse mortality at 2 years: low: n=109 (20%); moderate:
n=78 (39%) and high: n=150 (39%) (p=0.001); relapse at
two years: low: n=143 (23%); moderate: n=137 (28%) and
high: n=57 (52%) (p<0.001). To simplify this model, we
used identical risk scores for all outcome variables (overall
survival, relapse-free survival, non-relapse mortality, and
relapse). For this optimized score, we used the relapse-free
survival score because it affects both non-relapse mortali-
ty as well as relapse. This simplified score also allows a
clear separation of risk categories regarding overall sur-
vival at 2 years: low: n=96 (62%); moderate: n=168 (33%)
and high: n=73 (24%) (p<0.001); relapse-free survival at 2
years: low: n=96 (58%); moderate: n=168 (32%) and high:
n=73 (20%) (p<0.001); non-relapse mortality at 2 years:
low: n=96 (22%); moderate: n= 168 (37%) and high: n=73
(38%) (p=0.001); relapse at 2 years: low: n=96 (20%);
moderate: n=168 (31%) and high: n=73 (42%) (p<0.001)
(Figure 3).
Discussion
This large study of EBMT registry data shows that allo-
geneic stem cell transplantation is a curative therapy
option for patients with t-MDS or t-AML resulting in 3-
year event-free and overall survival rates of 33% and 35%,
respectively. In an earlier study of the EBMT a 3-year-
probability of disease-free survival of 35% was reported
for patients transplanted for t-MDS/t-AML (n=67) from
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Figure 3. Outcome (overall survival, relapse-free survival, non-
relapse mortality and relapse incidence) according to the simpli-
fied risk score model including age, complete remission and
abnormal cytogenetics (for details see text)(competing risk
model).
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HLA-identical siblings, which did not differ significantly
from the patients transplanted for primary MDS (37%,
n=712) or secondary AML (32%, n=106).18 For 70 patients
with t-MDS/t-AML the French Society of Bone Marrow
Transplantation reported a 28% event-free survival at 2
years after allogeneic stem cell transplantation from related
and unrelated donors.14 In a small single-center study
including 18 patients with MDS, the disease-free survival
after allogeneic stem cell transplantation was only 24% for
patients with t-MDS in comparison to 43% for those with
primary MDS.19 Several co-operative AML study groups
reported a worse overall survival for patients with t-AML
in comparison to those with de novo AML. An analysis of
the Medical Research Council (MRC)20 found a significant-
ly shorter overall survival for patients with t-AML (30% vs.
44%), which was in line with the results of the German
AML Cooperative group, which reported a median sur-
vival of 10 months for patients with t-AML in comparison
to 15 months for those with de novo AML (p=0.001).21
A recent update highlighted the impact of karyotype
aberrations in patients with t-AML, since t-AML patients
with favorable karyotype had a significantly better medi-
an survival than patients with an unfavorable karyotype
(26.7 vs. 5.6 months; p=0.02).22 This is in line with two
studies comparing t-MDS and de novo MDS. Neither study
found a significant difference in outcome after allogeneic
stem cell transplantation, when both groups were adjust-
ed for disease status and cytogenetic abnormalities.15,17
The importance of cytogenetic abnormalities in t-MDS/t-
AML is also highlighted in our analysis, and patients with
t-MDS/t-AML and abnormal intermediate or high risk
cytogenetics had a significantly higher risk of relapse (HR:
2.1) and reduced event-free survival (HR: 1.4) in multivari-
ate analysis. In a subanalysis of 261 patients for whom
complete cytogenetic data were available and who could
be classified as being at low, intermediate, or high risk,
those patients with low risk cytogenetics had a lower inci-
dence of relapse, resulting in improved event-free and
overall survival. 
A major finding of the study was the importance of cal-
endar year of transplantation on survival, which was due
to a marked reduction in non-relapse mortality over time.
This might be due in large part to improvements in unre-
lated transplants which exceeded 50% in older studies;23,24
however, in the present study the non-relapse mortality of
patients transplanted from unrelated donors did not differ
from that of patients undergoing related transplantation.
Besides the marked improvement over time, age, disease
group, and remission status were independent risk factors
for overall and event-free survival, which were also found
for de novo MDS and secondary AML.18 The median age of
the patients was 40 years and age was an independent risk
factor for survival. However, the number of older patients
increased over time: between 1981 and 1989 only 3% of
the patients were older than 50 years of age, between
1990 and 1999 this population increased to 18% and
between 2000 and 2006 39% of the patients were older
than 50 years of age. Despite this increase of older patients
there was still a significant improvement in survival in
recent years.
In contrast to the findings of an EBMT study, dose-
reduced conditioning was not associated with significant
differences compared to standard conditioning.25 Since
cytogenetic data were not complete, we were not able to
distinguish between alkylating- and topoisomerase II-
inhibitor-induced t-MDS or t-AML, which might have an
impact on outcome. We, therefore, tried to separate these
forms of t-MDS/t-AML by grouping patients with AML at
diagnosis and MDS at diagnosis and by using a cut-off of
54 months between diagnosis of the primary disease and
diagnosis of t-MDS/t-AML. For patients with AML at diag-
nosis, which is suggestive of topoisomerase II-inhibitor-
induced t-AML, a significantly higher incidence of relapse
was found in the multivariate analysis, although this could
be due to patients with AML not in complete remission at
tha time of transplantation.
To develop a simple risk score for patients with t-MDS/t-
AML who underwent allogeneic stem cell transplantation
we included the main risk factors of the multivariate analy-
sis: age (>40 years), remission status (not complete), and
abnormal cytogenetic features [excluding: inv(16), t(8;21),
and t(15;17)]. This model enabled a clear separation of the
patients into three risk groups (low, moderate and high),
predicting non-relapse mortality, incidence of relapse as
well as relapse-free and overall survival. This model high-
lighted that t-MDS/t-AML per se is not associated with a
bad prognosis, but that the outcome depends heavily on
age, remission status prior to stem cell transplantation, and
cytogenetic abnormalities. For example, a patient aged less
than 40 years in complete remission and without cytoge-
netic abnormalities who undergoes allogeneic stem cell
transplantation from a related or unrelated donor has an
estimated 2-year overall survival of 62%, and even if this
patient has a cytogenetic abnormality or is not in complete
remission at the time of transplantation, the estimated 2-
year overall survival is still 62%. This low-risk category
constituted 28% of the study population. In contrast, a
patient aged more than 40 years with abnormal cytogenet-
ics [excluding: inv(16), t(8;21) and t(15;17)] who is not in
complete remission at the time of transplantation has a
estimated 2-year overall survival of only 24%. This high-
risk group constituted 22% of the study population. If the
patient is aged more than 40 years, has normal cytogenet-
ics and is in complete remission at the time of transplanta-
tion (moderate risk), the 3-year probability of overall sur-
vival increases to 33%. 
We conclude that allogeneic stem cell transplantation for
patients with t-MDS/t-AML improved per calendar year
due to a marked reduction in non-relapse mortality. Not
being in complete remission at the time of transplantation,
abnormal intermediate or high risk cytogenetics and high-
er age of the patients are the most significant factors for
survival, and are data that can be easily used in a risk
model that predicts outcome.
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